Analytical Data
-
Gene name
TNFRSF13B
- Application
-
Alternative Names
Transmembrane activator and CAML interactor,
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
O14836
-
Expression Region
1-160aa
-
Molecular Weight
18.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFRSF13B, also known as TACI (Transmembrane Activator and CAML Interactor), is a member of the tumor necrosis factor receptor superfamily that plays a crucial role in the immune system. It is primarily expressed on B cells and is involved in regulating humoral immunity, including the activation and differentiation of B cells. Research has shown that mutations in TNFRSF13B are associated with eliciting immune deficiencies, particularly common variable immunodeficiency (CVID), leading to increased susceptibility to infections and autoimmune diseases. Given its pivotal role in immune regulation, the production of recombinant TNFRSF13B protein has garnered significant interest for both therapeutic and research purposes. Studying this recombinant protein can provide insights into its functional mechanisms, interactions with other immune molecules, and its role in B cell receptor signaling pathways. Moreover, understanding TNFRSF13B's structure-function relationship aids in developing potential immunotherapies to modulate immune responses in various pathological conditions. As researchers explore the potential of TNFRSF13B as a biomarker for immune-related disorders, the recombinant protein serves as a valuable tool for drug development and functional assays, ultimately advancing our understanding of immune system dynamics and improving therapeutic strategies for related diseases.
